Weekly Analysts’ Ratings Updates for Bristol Myers Squibb (BMY)

Bristol Myers Squibb (NYSE: BMY) has recently received a number of price target changes and ratings updates:

• 10/30/2026 – Bristol Myers Squibb had its “buy” rating reaffirmed by Bank of America.
• 10/30/2026 – Bristol Myers Squibb was given a new $70.00 price target by Truist Financial.
• 10/30/2026 – Bristol Myers Squibb had its price target lowered by Morgan Stanley from $41.00 to $40.00. They now have an “underweight” rating on the stock.
• 10/26/2026 – Bristol Myers Squibb had its price target lowered by Piper Sandler from $82.00 to $78.00. They now have an “overweight” rating on the stock.
• 10/22/2026 – Bristol Myers Squibb was downgraded by Zacks Research from “strong-buy” to “hold”.
• 10/19/2026 – Bristol Myers Squibb had its “sector perform” rating reaffirmed by Royal Bank Of Canada.
• 10/16/2026 – Bristol Myers Squibb was upgraded by The Goldman Sachs Group from “hold” to “strong-buy”.
• 10/13/2026 – Bristol Myers Squibb had its “market perform” rating reaffirmed by Sanford C. Bernstein.
• 10/13/2026 – Bristol Myers Squibb had its price target lowered by Wells Fargo & Company from $65.00 to $60.00. They now have an “equal weight” rating on the stock.
• 10/12/2026 – Bristol Myers Squibb had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $76.00 price target on the stock.
• 10/12/2026 – Bristol Myers Squibb had its “market perform” rating reaffirmed by William Blair.
• 10/9/2026 – Bristol Myers Squibb had its price target lowered by Bank of America from $71.00 to $66.00.
• 10/8/2026 – Bristol Myers Squibb had its price target raised by Rothschild & Co Redburn from $51.00 to $53.00. They now have a “neutral” rating on the stock.
• 10/8/2026 – Bristol Myers Squibb had its price target lowered by Cantor Fitzgerald from $59.00 to $53.00. They now have a “neutral” rating on the stock.
• 10/7/2026 – Bristol Myers Squibb had its “underweight” rating reaffirmed by Morgan Stanley. They now have a $41.00 price target on the stock, up from $40.00.
• 10/5/2026 – Bristol Myers Squibb was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $59.00 price target on the stock, down from $73.00.
• 9/23/2026 – Bristol Myers Squibb had its “neutral” rating reaffirmed by The Goldman Sachs Group. They now have a $63.00 price target on the stock, up from $61.00.
• 9/23/2026 – Bristol Myers Squibb was upgraded by Zacks Research from “hold” to “strong-buy”.
• 9/16/2026 – Bristol Myers Squibb had its “overweight” rating reaffirmed by Piper Sandler. They now have a $82.00 price target on the stock, up from $75.00.
• 9/10/2026 – Bristol Myers Squibb had its “hold” rating reaffirmed by HSBC. They now have a $65.00 price target on the stock, up from $60.00.

Bristol Myers Squibb Trading Up 3.3%

Shares of Bristol Myers Squibb stock traded up $2.07 during trading on Wednesday, hitting $63.78. The stock had a trading volume of 5,542,967 shares, compared to its average volume of 11,999,792. The company has a market capitalization of $130.37 billion, a PE ratio of 14.14, a P/E/G ratio of 0.32 and a beta of 0.20. The stock has a 50 day simple moving average of $62.60 and a 200 day simple moving average of $60.00. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a 1 year low of $45.26 and a 1 year high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business had revenue of $13.07 billion during the quarter, compared to analyst estimates of $12.72 billion. During the same period in the prior year, the firm earned $1.63 earnings per share. The firm’s revenue was up 6.9% compared to the same quarter last year. On average, research analysts expect that Bristol Myers Squibb Company will post 6.45 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.88%.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.05% of the company’s stock.

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.